肿瘤细胞治疗研究
英文原题：Therapeutic options for relapsed/refractory mantle cell lymphoma.
套细胞淋巴瘤（MCL）是一种少见的非霍奇金淋巴瘤亚型，免疫化疗联合或不联合大剂量治疗及自体干细胞移植仍是标准一线治疗方案。
套细胞淋巴瘤（MCL）是一种少见的非霍奇金淋巴瘤亚型，免疫化疗联合或不联合大剂量治疗及自体干细胞移植仍是标准一线治疗方案。尽管疗效明确，患者仍不可避免地复发并需要后续治疗。在本综述中，我们讨论复发MCL管理中的关键治疗策略，深入涵盖支持在首次或后续复发时使用共价Bruton酪氨酸激酶（BTK）抑制剂的资料。我们描述经BTK抑制剂治疗后进展患者的结局，并讨论共价BTKi耐药的机制以及共价BTKi治疗后的治疗选择。在此情况下的选择可能取决于治疗可及性、患者和医生的偏好，以及患者的年龄和合并症状态。我们讨论抗CD19CAR-T 细胞治疗的近期快速发展，以及异基因干细胞移植和新型疗法的效用，例如非共价、可逆性BTK抑制剂；ROR1抗体药物偶联物；以及双特异性抗体。
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which immunochemotherapy, with or without high-dose therapy, and autologous stem cell transplantation remain standard frontline therapies. Despite their clear efficacy, patients inevitably relapse and require subsequent therapy. In this review, we discuss the key therapeutic approaches in the management of relapsed MCL, covering in depth the data supporting the use of covalent Bruton tyrosine kinase (BTK) inhibitors at first or subsequent relapse. We describe the outcomes of patients progressing through BTK inhibitors and discuss the mechanisms of covalent BTKi resistance and treatment options after covalent treatment with BTKi. Options in this setting may depend on treatment availability, patient's and physician's preference, and the patient's age and comorbidity status. We discuss the rapid recent development of anti-CD19 chimeric antigen receptor T-cell therapy, as well as the utility of allogenic stem cell transplantation and novel therapies, such as noncovalent, reversible BTK inhibitors; ROR1 antibody drug conjugates; and bispecific antibodies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
